Q3 EPS Estimate for ACADIA Pharmaceuticals Raised by Analyst

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a note issued to investors on Wednesday, August 5th. HC Wainwright analyst A. Ghosh now forecasts that the biopharmaceutical company will post earnings of $0.15 per share for the quarter, up from their prior forecast of $0.13. HC Wainwright has a “Hold” rating on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.39 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q4 2026 earnings at $0.20 EPS and FY2027 earnings at $1.89 EPS.

Other equities analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday, June 29th. Citizens Jmp boosted their target price on shares of ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Stifel Nicolaus upped their price target on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a “hold” rating in a report on Tuesday, July 21st. Bank of America reiterated a “buy” rating and issued a $14.50 price target on shares of ACADIA Pharmaceuticals in a research note on Wednesday, July 29th. Finally, Canaccord Genuity Group raised their price objective on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a report on Monday, June 29th. Thirteen analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.53.

ACADIA Pharmaceuticals Trading Up 6.1%

ACAD opened at $28.80 on Thursday. The company has a market cap of $4.93 billion, a P/E ratio of 12.97, a PEG ratio of 18.82 and a beta of 0.81. The company’s 50 day moving average is $24.10 and its 200-day moving average is $23.22. ACADIA Pharmaceuticals has a 1-year low of $19.69 and a 1-year high of $29.17.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.07 by $0.11. The firm had revenue of $308.00 million during the quarter, compared to the consensus estimate of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.38% and a net margin of 33.42%.The business’s quarterly revenue was up 16.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.16 earnings per share.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank bought a new stake in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $40,266,000. Millennium Management LLC raised its holdings in ACADIA Pharmaceuticals by 2,052.1% during the 3rd quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company’s stock worth $31,652,000 after purchasing an additional 1,414,315 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in ACADIA Pharmaceuticals by 390.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company’s stock worth $35,187,000 after purchasing an additional 1,312,426 shares during the last quarter. First Trust Advisors LP lifted its position in shares of ACADIA Pharmaceuticals by 47.3% in the 1st quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock worth $74,435,000 after purchasing an additional 1,073,834 shares during the period. Finally, Logos Global Management LP acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter worth approximately $22,704,000. 96.71% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the company’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the sale, the executive vice president owned 18,994 shares in the company, valued at approximately $496,313.22. The trade was a 46.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider James Kihara sold 5,401 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total value of $114,393.18. Following the completion of the sale, the insider directly owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. The trade was a 18.06% decrease in their position. The disclosure for this sale is available in the SEC filing. 26.20% of the stock is owned by company insiders.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Second-quarter results exceeded expectations. ACADIA reported adjusted EPS of $0.18, ahead of the $0.06 consensus estimate and above $0.16 a year earlier. Revenue rose 16.4% year over year to $308 million, exceeding expectations of approximately $295.5 million. Acadia Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Commercial momentum supported the beat. Strong sales of DAYBUE and NUPLAZID, along with continued patient demand and DAYBUE’s STIX uptake, drove the performance. Management described execution across both products as strong. Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year 2026 revenue guidance was raised. ACADIA now expects revenue of $1.2 billion to $1.3 billion, compared with a consensus estimate near $1.2 billion. The improved outlook reinforces expectations for continued growth from its marketed products. ACAD Q2 Earnings and Revenues Beat, 2026 View Raised on Product Sales
• Positive Sentiment: Citizens JMP increased its price target to $36 from $35 and maintained a “market outperform” rating, implying further upside based on the cited $28.80 reference price. Citizens JMP Raises ACADIA Price Target

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.